Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2019-08-29 Governance Information
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Appendix 4G 14 pages 236.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2019. The document is a corporate governance statement that is lodged with the ASX at the same time as the annual report but is not the annual report itself. It does not contain financial statements or substantive financial data but rather governance disclosures and compliance information. This type of document fits the category of Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a full governance disclosure rather than a brief announcement or certification. Therefore, the correct classification is CGR with high confidence.
2019-08-29 English
Quarterly Update & Appendix 4C 7 pages 222.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly report for the period ending 30 June 2019' and contains detailed financial data including consolidated statements of cash flows, cash equivalents, payments to directors, financing facilities, and estimated cash outflows for the next quarter. It also includes operational updates and corporate changes such as board appointments and company secretary appointments. The presence of detailed financial statements and operational commentary for a quarter indicates this is a comprehensive interim financial report. The document is over 12,000 characters, so it is not a brief announcement or a report publication notice. It complies with Listing Rule 4.7B, which is typical for quarterly reports in the Australian market. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2019
2019-07-30 English
Response to ASX Price and Volume Query 3 pages 260.0KB
Regulatory Filings Classification · 100% confidence The document is a letter from the Australian Securities Exchange (ASX) to Neurotech International Limited (NTI) regarding a price and volume query about recent trading activity in NTI's securities. The letter requests information from the company about any undisclosed material information that could explain the trading activity, compliance with listing rules, and authorization of responses. The company responds confirming no undisclosed information and compliance with listing rules. This document is a regulatory inquiry and response related to market compliance and disclosure obligations, not a financial report, earnings release, or management discussion. It is a regulatory filing related to compliance and market conduct rather than a report or announcement of financial results or corporate actions. The document length is 7245 characters, which is relatively short and consists mainly of correspondence and compliance information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-07-17 English
Neurotech launches Mente Clinic 2 pages 86.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new virtual clinic product (Mente Clinic) by Neurotech International Limited. It describes the features of the product, the Early Adopter Program, and availability of the Mente iOS app. There is no indication of financial data, regulatory filings, shareholder votes, or management changes. The document is promotional and informational about a product launch rather than a financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content aligns best with a general company announcement or update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2019-06-04 English
Response to ASX Price and Volume Query 3 pages 686.2KB
Regulatory Filings Classification · 100% confidence The document is a letter from the Australian Securities Exchange (ASX) to Neurotech International Limited regarding a price and volume query about the company's securities. It includes a request for information about recent trading activity and compliance with listing rules, and a response letter from the company addressing these queries. The content is focused on regulatory compliance and market disclosure rather than financial results, management changes, or detailed financial reporting. It is a regulatory communication related to market conduct and disclosure obligations, not a financial report or announcement of financial results. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-06-04 English
Change in substantial holding 3 pages 66.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001 Section 671B, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder in a company, including dates, share counts, and nature of changes. This form is a regulatory notification about changes in major shareholdings, not a financial report, earnings release, or management information. It specifically reports changes in substantial shareholdings as required by law. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory filing about shareholding changes.
2019-06-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.